期刊
HLA
卷 95, 期 2, 页码 95-103出版社
WILEY
DOI: 10.1111/tan.13759
关键词
HIV; HLA
资金
- National Institutes of Health [P50 8 P50 AI150464-13]
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health [HIVRAD P01 P01AI10014]
Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) remains one of the most important current threats to global public health. Since its identification in the early 1980s, at least 75 million people have been infected with HIV-1, the virus that causes AIDS. Although antiretroviral drugs are effective at prolonging life after infection in the developed world, they are associated with significant side effects and are not in widespread use in the developing world. The best way to control the AIDS epidemic would be a vaccine that protects against infection by HIV-1. Most vaccines work by inducing antibodies in serum or mucosa that block infection or prevent invasion of the bloodstream. Here, I describe background related to my laboratory's attempts to develop an immunogen that would elicit protective antibodies against HIV-1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据